Chemotherapy drug paclitaxel can target and reduce the migrating cancer cells that are responsible for the development of tumor metastases, according to a study by a research team at the University of California, Riverside. The findings of the study are published in the Journal of Medicinal Chemistry.
Until now, paclitaxel has only been used to target rapidly dividing cancer cells. The team was successful in getting the drug to piggyback on 123B9, an agent they devised to target an oncogene called EphA2 (ephrin type-A receptor 2). EphA2 spreads cancer by allowing malignant cells to migrate from the primary tumor into circulation and eventually to adhere to other tissues.
Brain Tumor
Brain tumors are the abnormal growth of brain cells that may be benign or metastatic. Brain tumors account for about 2.4% of all the tumor diagnosesandare most challenging due to their critically delicate location.
Advertisement
‘Binding of 123B9 can cause the oncogene to reduce the number of circulating cancer cells and produce less metastatic cells.’
Tweet it Now
"Once this novel tumor-homing agent binds to the EphA2 receptor, the oncogene functions as a cancer-specific molecular Trojan horse for paclitaxel, carrying the drug inside the cancel cell, killing the cell, and thwarting metastasis," said Maurizio Pellecchia, a professor of biomedical sciences at UCR's School of Medicine who led the research. "Without the targeting agent, paclitaxel cannot hitch a ride on EphA2."
Tumor metastasis is a leading cause of patient morbidity and mortality, and no treatments are currently available that specifically target metastasis formation. Cancer cells depend on a number of oncogenes, like EphA2, to form metastasis, the medical term for cancer spreading from the primary site to other regions in the body, accomplished when cancer cells break away from the primary site, travel through the blood or lymph system, and form new tumors elsewhere in the body.
![Zika Virus: The New Treatment For Brain Tumor]( "Zika Virus: The New Treatment For Brain Tumor")
When infected with Zika virus, brain tumor cells form metabolites such as digoxin, a molecule that kills glioblastoma (brain cancer) cells.
Pellecchia and his colleagues found that when 123B9 binds to the extracellular region of the EphA2 receptor expressed in cancer cells, it causes the oncogene to internalize and degrade inside the cell, thus preventing cancer cells from entering circulation and metastasizing.
"Because this binding causes EphA2 internalization, we also sought to conjugate 123B9 with paclitaxel and thus direct the drug to migrating cancer cells," said Pellecchia, who holds the Daniel Hays Chair in Cancer Research at UCR.
Recent collaborative work between UCR and Cedars-Sinai Medical Center in Los Angeles demonstrated that in animal models of human breast cancer, mice treated with 123B9 that was conjugated with paclitaxel had significantly fewer circulating cancer cells in the blood compared to mice that were not treated or even treated with paclitaxel alone.
"Our work predicts that reducing the number of circulating cancer cells produces less metastasis," Pellecchia said. "Indeed, in a second tumor model of metastatic breast cancer, we demonstrated that mice treated with the EphA2-targeting paclitaxel conjugate presented nearly no lung metastases, while a large numbers of lesions were observed in both untreated mice and in mice treated with just paclitaxel."
Pellecchia said the road to a therapeutic for human trials is still long and includes the iterative design and synthesis of more potent and selective agents.
"Nonetheless, the proof of concept studies we have obtained thus far are extremely encouraging, and we are confident that with proper support and efforts we could translate our findings into experimental therapeutics for a variety of solid tumors that are driven by EphA2 overexpression, including breast, lung, prostate, pancreatic, and ovarian cancers," said Pellecchia, who serves as the founding director of the Center for Molecular and Translational Medicine at UCR.
He noted that while these studies solidify UCR's partnership with Cedars-Sinai Medical Center, the research team moving forward is expanding. Already, it includes UCR's Jikui Song, an assistant professor of biochemistry, and Dr. Samar Nahas, an assistant clinical professor of gynecology and oncology in the School of Medicine.
Source: Eurekalert
Zika Virus: The New Treatment For Brain Tumor
When infected with Zika virus, brain tumor cells form metabolites such as digoxin, a molecule that kills glioblastoma (brain cancer) cells.
Advertisement
Pellecchia and his colleagues found that when 123B9 binds to the extracellular region of the EphA2 receptor expressed in cancer cells, it causes the oncogene to internalize and degrade inside the cell, thus preventing cancer cells from entering circulation and metastasizing.
"Because this binding causes EphA2 internalization, we also sought to conjugate 123B9 with paclitaxel and thus direct the drug to migrating cancer cells," said Pellecchia, who holds the Daniel Hays Chair in Cancer Research at UCR.
Recent collaborative work between UCR and Cedars-Sinai Medical Center in Los Angeles demonstrated that in animal models of human breast cancer, mice treated with 123B9 that was conjugated with paclitaxel had significantly fewer circulating cancer cells in the blood compared to mice that were not treated or even treated with paclitaxel alone.
"Our work predicts that reducing the number of circulating cancer cells produces less metastasis," Pellecchia said. "Indeed, in a second tumor model of metastatic breast cancer, we demonstrated that mice treated with the EphA2-targeting paclitaxel conjugate presented nearly no lung metastases, while a large numbers of lesions were observed in both untreated mice and in mice treated with just paclitaxel."
Pellecchia said the road to a therapeutic for human trials is still long and includes the iterative design and synthesis of more potent and selective agents.
"Nonetheless, the proof of concept studies we have obtained thus far are extremely encouraging, and we are confident that with proper support and efforts we could translate our findings into experimental therapeutics for a variety of solid tumors that are driven by EphA2 overexpression, including breast, lung, prostate, pancreatic, and ovarian cancers," said Pellecchia, who serves as the founding director of the Center for Molecular and Translational Medicine at UCR.
He noted that while these studies solidify UCR's partnership with Cedars-Sinai Medical Center, the research team moving forward is expanding. Already, it includes UCR's Jikui Song, an assistant professor of biochemistry, and Dr. Samar Nahas, an assistant clinical professor of gynecology and oncology in the School of Medicine.
Source: Eurekalert
Tumor Progression Due to Communication Between Lung Tumors and Bones
General study identifying interaction among tumor cells, bone marrow and immune cells opens new avenue for immunotherapy
Advertisement
 Controlling Gene Expression may Stop Tumor Growth in Ewing SarcomaEwing sarcoma may be treated effectively by controlling the expression of the genes EWS and FLI-1. It also controls the growth of cells in other types of pediatric tumors originating from neural stem cells. | Advertisement
|
Advertisement
Recommended Reading
Latest Drug News
Addressing the unmet needs of Parkinson's Disease by providing disease-modifying therapies could bring about a major shift in the way that patients are treated.
Microrobots could swirl through a person's blood stream, search for targeted areas to treat for various ailments.
Supplementation with multivitamins is an inexpensive way for older adults to slow down memory loss.
Some people with an aggressive blood cancer called acute myeloid leukemia (AML) may soon have a new drug option called Ivosidenib that blocks the activity of IDH1 gene.
In case of cardiac failure where the ejection fraction is greater than 40%, sacubitril/valsartan can prove to be quite beneficial